[HTML][HTML] EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or …
R Buhl, M Dreher, M Mattiucci-Guehlke… - Advances in …, 2023 - Springer
Abstract Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …
EVELUTÒ: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA …
RBMDM Mattiucci, GRESS Eckhardt… - Adv Ther, 2023 - openscience.ub.uni-mainz.de
Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no
longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) …
longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) …
EVELUT®: dyspnoea and symptom burden in COPD patients switching from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
R Buhl, M Dreher, M Mattiucci-Guehlke, S Eckhardt… - 2022 - Eur Respiratory Soc
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends that COPD patients who are dyspnoeic despite use of long-acting β 2-agonist …
recommends that COPD patients who are dyspnoeic despite use of long-acting β 2-agonist …
[引用][C] Lung function and exacerbations in patients with COPD escalated to triple therapy: The RETRIEVE real‐world study
S Tryfon, E Papadopoulou, M Bertoli, K Exarchos… - …, 2023 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death
worldwide. 1 Exacerbations of the disease, that call for additional therapeutic measures, are …
worldwide. 1 Exacerbations of the disease, that call for additional therapeutic measures, are …
Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial
DA Lipson, F Barnhart, I Boucot, C Crim, N Brealey… - 2018 - Eur Respiratory Soc
Rationale: Current GOLD strategy document positions both combination regimens of inhaled
corticosteroid plus a long-acting β2-agonist [ie ICS/LABA] and long-acting muscarinic …
corticosteroid plus a long-acting β2-agonist [ie ICS/LABA] and long-acting muscarinic …
Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns
SA Brunton, DK Hogarth - Postgraduate Medicine, 2023 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity
and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive …
and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive …
A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study …
R Buhl, M Dreher, S Korn, C Taube… - … Journal of Chronic …, 2020 - Taylor & Francis
Background The Global Initiative for Chronic Obstructive Lung Disease 2020 report
recommends that patients with chronic obstructive pulmonary disease (COPD) suffering from …
recommends that patients with chronic obstructive pulmonary disease (COPD) suffering from …
[HTML][HTML] LABA/LAMA as first-line therapy for COPD: a summary of the evidence and guideline recommendations
M Miravitlles, T Kawayama, M Dreher - Journal of Clinical Medicine, 2022 - mdpi.com
Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …
symptomatic patients with COPD, either as initial/first-line treatment or for second …
Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive …
JC Samp, MJ Joo, GT Schumock… - … : The Journal of …, 2017 - Wiley Online Library
Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
[HTML][HTML] Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database
JK Quint, J Montonen, DB Esposito, X He, L Koerner… - Advances in …, 2021 - Springer
Introduction In patients with chronic obstructive pulmonary disease (COPD), treatment with
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
相关搜索
- copd patients lama laba
- symptom burden laba ics
- symptom burden copd patients
- real world laba ics
- real world copd patients
- symptom burden real world
- tiotropium olodaterol laba ics
- health status lama laba
- ics laba outcomes in copd
- copd patients health status
- effectiveness and safety laba ics
- lung function lama laba
- lung function patients with copd
- laba lama summary of the evidence
- laba lama guideline recommendations
- ics laba meta analysis